How many etiological subtypes of breast cancer: Two, three, four, or more?

Journal of the National Cancer Institute

Volumn 106, Issue 8, 2014, Pages

  Anderson, William F ^a   Rosenberg, Philip S ^a   Prat, Aleix ^b   Perou, Charles M ^c   Sherman, Mark E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; MESSENGER RNA; RNA; TUMOR MARKER; TUMOR PROTEIN;

ADVANCED CANCER; AGE DISTRIBUTION; BIOSTATISTICS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MODEL; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CELLS BY BODY ANATOMY; CLINICAL FEATURE; DISEASE COURSE; EVALUATION STUDY; GENETIC SUSCEPTIBILITY; HUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; AGE; BREAST TUMOR; CHEMISTRY; CLASSIFICATION; EVIDENCE BASED MEDICINE; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; INCIDENCE; PATHOLOGY; PROGNOSIS; RISK FACTOR;

AGE DISTRIBUTION; AGE FACTORS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; NEOPLASM PROTEINS; PROGNOSIS; RISK FACTORS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84906996719     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju165     Document Type: Review

References (189)

1. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52(1-3):261-288.
2. Anderson WF, Matsuno RK. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst. 2006;98(14):948-951.
3. Li JJ, Li SA, Mohla S, Rochefort H, Maudelonde T. Hormonal Carcinogenesis V. Advances in Experimental Medicine and Biology. Vol. 617. New York: Springer; 2008. ISBN 978-0-387-69078-0.
4. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403): 353-360.
5. Ithimakin S, Day KC, Malik F, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013;73(5):1635-1646.
6. Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013;73(12):3489-3493.
7. Korkaya H, Wicha MS. Breast cancer stem cells: we've got them surrounded. Clin Cancer Res. 2013;19(3):511-513.
8. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009;15(8):842-844.
9. Prat A, Adamo B, Fan C, et al. Gene expression analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Scientific Rep. 2013;3:1-12.
10. Armitage P, Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer. 1957;11(2):161-169.
11. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8(1):1-12.
12. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1(2):157-162.
13. Doll R. Commentary: the age distribution of cancer and a multistage theory of carcinogenesis. Int J Epidemiol. 2004;33(6):1183-1184.
14. Frank SA. Commentary: mathematical models of cancer progression and epidemiology in the age of high throughput genomics. Int J Epidemiol. 2004;33(6):1179-1181.
15. Moolgavkar SH. Commentary: fifty years of the multistage model: remarks on a landmark paper. Int J Epidemiol. 2004;33(6):1182-1183
16. Clemmesen J. Carcinoma of the breast. Br J Radiol. 1948;21(252):583-590.
17. Clemmesen J. On the etiology of some human cancers. J Natl Cancer Inst. 1951;12(1):1-21.
18. Muguti GI. Experience with breast cancer in Zimbabwe. J R Coll Surg Edinb. 1993;38(2):75-78.
19. Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS. Age-period-cohort analysis of breast cancer mortality. Anticancer Res. 1995;15(2):511-515
20. Sant M, Gatta G, Micheli A, et al. Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991;27(8):981-984.
21. Thomas DB. Breast cancer in men. Epidemiol Rev. 1993;15(1):220-231.
22. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. "Hormonal" risk factors, "breast tissue age: and the age-incidence of breast cancer. Nature. 1983;303(5920):767-770.
23. Pathak DR, Whittemore AS. Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992;135(2):153-168.
24. Rosner B, Colditz GA. Nurses' Health Study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst. 1996;88(6):359-364.
25. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 1994;139(8):819-835.
26. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 1980;65(3):559-569.
27. Lilienfeld AM, Johnson EA. The age distribution in female breast and genital cancers. Cancer. 1955;8:875-882.
28. De Waard F. Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst. 1979;63(3):549-552.
29. De Waard F, Baanders-van Halewijn EA, Huizinga J. The bimodal age distribution of patients with mammary carcinoma; evidence for the existence of 2 types of human breast cancer. Cancer. 1964;17(2):141-151.
30. De Waard F, De Laive JWJ, Baanders-van Halewijn EA. On bimodal age distribution of mammary carcinoma. Br J Cancer. 1960;14(3):437-448.
31. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End results database. Breast Cancer Res Treat. 2002;76(1):27-36.
32. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66(1):65-74.
33. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999;10(5):431-437.
34. Tarone RE, Chu KC. The greater impact of menopause on ER-than ER+ breast cancer incidence: a possible explanation (United States). Cancer Causes Control. 2002;13(1):7-14.
35. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 1998;148(12):1195-1205.
36. Morabia A, Flandre P. Misclassification bias related to definition of menopausal status in case-control studies of breast cancer. Int J Epidemiol. 1992;21(2):222-228.
37. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM. Agerelated crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst. 2008;100(24):1804-1814.
38. Anderson WF, Matsuno RK, Sherman ME, et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control. 2007;18(4):439-447.
39. Anderson WF, Chen BE, Brinton LA, Devesa SS. Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes Control. 2007;18(10):1187-1198.
40. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol. 2009;27(32):5308-5311.
41. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London: Nuffield Provincial Hospitals Trust; 1972.
42. Peto R. Statistical Aspects of Cancer Trials. London: Chapman and Hall; 1982.
43. Anderson WF, Chu KC, Chatterjee N, Brawley OW, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2001;19(1):18-27.
44. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat. 2005;90(2):127-137.
45. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age frequency distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1899-1905.
46. Desantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in US women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20(5):733-739.
47. Anderson WF, Katki HA, Rosenberg PS. Breast cancer incidence in the United States: urrent and future trends. J Natl Cancer Inst. 2011;103(18):1397-1402.
48. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA. Cancer J Clin. 2014;64(1):52-62.
49. Berry DA, Ravdin PM. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst. 2007;99(15):1139-1141.
50. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795.
51. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst. 1999;91(23):2020-2028.
52. Narod SA, Dube MP. Biologic characteristics of interval and screendetected breast cancers. J Natl Cancer Inst. 2001;93(2):151-152.
53. Anderson WF, Rosenberg PS, Petito L, et al. Divergent estrogen receptorpositive and-negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer. 2013;133(9):2201-2206.
54. Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat. 2013;138(3):665-673.
55. Pfeiffer RM, Carroll RJ, Wheeler W, Whitby D, Mbulaiteye S. Combining assays for estimating prevalence of human herpesvirus 8 infection using multivariate mixture models. Biostatistics. 2008;9(1):137-151.
56. Rosenberg PS, Anderson WF. Proportional hazard models and age-periodcohort analysis of cancer rates. Stat Med. 2010;29(11):1228-1238
57. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39(2):311-324.
58. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1128-1135.
59. Marcus JN, Page DL, Watson P, Narod SA, Lenoir GM, Lynch HT. BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer. 1997;80(S3):543-556.
60. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6(3):782-789.
61. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology (Phila). 2002;34(4):309-314.
62. Rosenberg PS, Anderson WF. Age-period-cohort models in cancer surveillance research: ready for prime time? Cancer Epidemiol Biomarkers Prev. 2011;20(7):1263-1268.
63. Moolgavkar SH, Stevens RG, Lee JA. Effect of age on incidence of breast cancer in females. J Natl Cancer Inst. 1979;62(3):493-501.
64. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4-66.
65. MacMahon B. Breast cancer at menopausal ages: an explanation of observed incidence changes. Cancer. 1957;10(5):1037-1044.
66. Lane-Claypon JE. A further report on cancer of the breast with special reference to its associated antecedent conditions. Rep Public Health Med Subj (Lond). 1926;32.
67. MacMahon B, Cole P, Lin TM, et al. Age at first birth and breast cancer risk. Bull World Health Organ. 1970;43(2):209-221.
68. Cummings P, Weiss NS, McKnight B, Stanford JL. Estimating the risk of breast cancer in relation to the interval since last term pregnancy. Epidemiology. 1997;8(5):488-494.
69. Thompson WD. Age at and time since: modeling temporal aspects of exposure. Epidemiology. 1997;8(5):471-473.
70. Woods KL, Smith SR, Morrison JM. Parity and breast cancer: evidence of a dual effect. Br Med J. 1980;281(6237):419-421.
71. Lubin JH, Burns PE, Blot WJ, et al. Risk factors for breast cancer in women in northern Alberta, Canada, as related to age at diagnosis. J Natl Cancer Inst. 1982;68(2):211-217.
72. Janerich DT, Hoff MB. Evidence for a crossover in breast cancer risk factors. Am J Epidemiol. 1982;116(5):737-742.
73. Bruzzi P, Negri E, La Vecchia C, et al. Short term increase in risk of breast cancer after full term pregnancy. BMJ. 1988;297(6656):1096-1098.
74. Williams EM, Jones L, Vessey MP, McPherson K. Short term increase in risk of breast cancer associated with full term pregnancy. BMJ. 1990;300(6724):578-579.
75. Hsieh C, Pavia M, Lambe M, et al. Dual effect of parity on breast cancer risk. Eur J Cancer. 1994;30A(7):969-973.
76. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 1994;331(1):5-9.
77. Leon DA, Carpenter LM, Broeders MJ, Gunnarskog J, Murphy MF. Breast cancer in Swedish women before age 50: evidence of a dual effect of completed pregnancy. Cancer Causes Control. 1995;6(4):283-291.
78. Albrektsen G, Heuch I, Kvale G. The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer. 1995;72(2):480-484.
79. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO. Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J Cancer. 1998;77(3):330-332.
80. Wohlfahrt J, Olsen JH, Melby M. Breast cancer risk after childbirth in young women with family history (Denmark). Cancer Causes Control. 2002;13(2):169-174.
81. Pathak DR. Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Causes Control. 2002;13(4):295-298.
82. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997;336(2):81v85.
83. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6(4):281-291.
84. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009;14(2):87-98
85. Tiede B, Kang Y. From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res. 2011;21(2):245-257.
86. Kobayashi S, Sugiura H, Ando Y, et al. Reproductive history and breast cancer risk. Breast Cancer. 2012;19(4):302-308.
87. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218-228.
88. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;123(1):123-139.
89. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 2010;116(21):4933-4943.
90. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
91. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-477.
92. Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat. 2002;72(2):107-115.
93. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187-195.
94. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
95. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113(7):1521-1526.
96. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130(2):587-597.
97. Kotsopoulos J, Lubinski J, Salmena L, et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42.
98. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 2013;137(2):579-587.
99. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2078-2086.
100. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997;216(1):28-43.
101. Wu Q, Ishikawa T, Sirianni R, et al. 27-Hydroxycholesterol promotes cell-autonomous, er-positive breast cancer growth. Cell Rep. 2013;5(3):637-645.
102. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-1098.
103. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370(6):572-573.
104. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1407-1411.
105. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer. 2004;111(5):762-771.
106. Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast (Edinburgh, Scotland). 2004;13(2):85-92.
107. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005;14(3):656-661.
108. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193-201.
109. Teras LR, Goodman M, Patel AV, Diver WR, Flanders WD, Feigelson HS. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 2011;22(4):573-579.
110. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568.
111. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16(12):3731-3735.
112. Schairer C, Li Y, Frawley P, et al. Risk factors for inflammatory breast cancer and other invasive breast cancer. J Natl Cancer Inst. 2013;105(18):1373-1384.
113. Tarone RE. Breast cancer trends among young women in the United States. Epidemiology. 2006;17(5):588-590.
114. Lidegarrd O, Kroman N. The epidemiology of breast cancer. Eur Clinics Obstet Gynaecol. 2005;1(1):24-28.
115. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a populationbased study. Lancet Oncol. 2012;13(8):790-801.
116. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80(3):435-441.
117. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998;83(2):310-319.
118. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10(6):2029-2034.
119. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-361.
120. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054.
121. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res. 2008;14(24):8000-8009.
122. Li J, Humphreys K, Darabi H, et al. A genome-wide association scan on estrogen receptor-negative breast cancer. Breast Cancer Res. 2010;12(6):R93.
123. Figueroa JD, Garcia-Closas M, Humphreys M, et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20(23):4693-4706.
124. Broeks A, Schmidt MK, Sherman ME, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20(16):3289-3303.
125. Haiman CA, Chen GK, Vachon CM, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011;43(12):1210-1214.
126. Hein R, Maranian M, Hopper JL, et al. Comparison of 6q25 breast cancer hits from Asian and European genome wide association studies in the Breast Cancer Association Consortium (BCAC). PLoS One. 2012;7(8):e42380.
127. Lambrechts D, Truong T, Justenhoven C, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat. 2012;33(7):1123-1132.
128. Stevens KN, Fredericksen Z, Vachon CM, et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res. 2012;72(7):1795-1803.
129. Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392-398.
130. Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371-384.
131. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73(7):2025-2030.
132. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-1823.
133. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
134. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
135. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet. 2002;32(Suppl):533-540.
136. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
137. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
138. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
139. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197-204.
140. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264-271.
141. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10(4):R67.
142. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004;10(16):5508-5517.
143. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8(4):R34.
144. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res. 2007;143(1):109-118.
145. Winer EP, Carey LA, Dowsett M, Tripathy D. Beyond anatomic staging: are we ready to take the leap to molecular classification? In: Perry MC, ed. American Society of Clinical Onocolgy Education Book. Alexandria, VA: American Society of Clinical Oncology; 2005:46-59.
146. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expressionbased predictors for breast cancer. N Engl J Med. 2006;355(6):560-569.
147. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
148. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29(17):2301-2304.
149. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
150. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217-1226.
151. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
152. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685.
153. Wo JY, Taghian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010;77(1):188-196.
154. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expressionbased assays for breast oncologists. Nat Rev Clin Oncol. 2012;9(1):48-57.
155. Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1848-1855.
156. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Disc. 2013;3(1):27-34.
157. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747.
158. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123-133.
159. Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31(2):203-209.
160. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
161. Ciriello G, Sinha R, Hoadley KA, et al. The molecular diversity of luminal A breast tumors. Breast Cancer Res Treat. 2013;141(3):409-420.
162. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7(1):127.
163. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic? J Clin Oncol. 2009;27(8):1153-1154.
164. Gierach GL, Burke A, Anderson WF. Epidemiology of triple negative breast cancers. Breast Dis. 2010;32(1-2):5-24.
165. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2010;15(Suppl 5):39-48.
166. Lusa L, McShane LM, Reid JF, et al. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst. 2007;99(22):1715-1723.
167. Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. Apr 2010;11(4):339-349.
168. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11(8):718-719; author reply 720-721.
169. Sorlie T, Borgan E, Myhre S, et al. The importance of gene-centring microarray data. Lancet Oncol. 2010;11(8):719-720; author reply 720-721.
170. Hoadley KA, Yau C, Wolf DM, et al. Multi-platform integration of 12 cancer types reveals cell-of-origin with distinct molecular signatures. Cell. 2014; in press.
171. Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977-2006): a population-based cohort study. Breast Cancer Res. 2012;12(4):R54.
172. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;135(1):301-306.
173. Anderson WF, Luo S, Chatterjee N, et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 2009;113(1):189-196.
174. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011;127(2):471-478.
175. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010;12(6):R99.
176. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 2012;14(2):R55.
177. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094-1101.
178. SEER-18. Surveillance, Epidemiology, and End Results (SEER) program (www.seer.cancer.gov) SEER∗Stat Database: Incidence-SEER 18 Regs Custom Data (includes additional CS SSF data for 2010 cases), Nov 2012 Sub (2000-2010) -Linked To County Attributes-Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released May 2013, based on November 2012 submission. 2012. www.seer. cancer.gov. Accessed May 1, 2014.
179. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
180. Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013;32(5):617-628.
181. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003;36(Suppl 1):73-84.
182. Goodman MT, Hernandez BY, Hewitt S, et al. Tissues from populationbased cancer registries: a novel approach to increasing research potential. Hum Pathol. Jul 2005;36(7):812-820.
183. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
184. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast And Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
185. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005;23(8):1616-1622.
186. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast cancer trends in the United States. J Clin Oncol. 2007;25(25):3923-3929.
187. Rosenberg PS. Hazard function estimation using B-splines. Biometrics. 1995;51(3):874-887.
188. Akaike H. Information theory and an extension of the maximum likelihood principle. Paper presented at 2nd International Symposium on Information Theory; 1973; Budapest, Hungary.
189. Efron B, Tibshirani R. An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability 57. New York: Chapman & Hall; 1993.